World Cancer Assay Markets Human Genome Project Drives Industry Developments “The Human Genome Project has generated a tremendous amount of information regarding the makeup and structure of the human genome— the implications of which are incredible for the future of medicine in the areas of diagnosis, prognosis, and treatment of cancer.” Clinical Diagnostics Analyst Team Frost & Sullivan
Detailed insights into recent developments and trends Drivers, restraints, challenges, and strategic recommendations Analyst insights into ‘hot topics’ and emerging applications in the world cancer assay market Market-sizing and competitive analysis Market forecasts and opportunity analyses Quarterly assessments End-user analysis Key Features
Coverage – The World Proven methodology using extensive primary and secondary data as well as research Focused information and strategies that cover business and technology issues Credible data and analyses that highlight industry dynamics Precise strategies to help you create winning business plans What We Offer
Current Market Participants Find out where you stand in comparison with the competitors Assess current and future drivers as well as restraints Determine and exploit new market share opportunities New Entrants Analyze the associated challenges Calculate timescales for strategy implementation Position yourself to capitalize on the unmet needs of the market Investment Community Analyze long-term strategies of companies Determine participants that will outperform the competition Assess the attractiveness of investing in the market Benefits
Affymetrix, Inc. BD Biosciences Clontech Cambio, Inc. Cytocell Ltd. Digene Corporation Genzyme Corporation Myriad Genetics, Inc. Ventana Medical Systems, Inc. Vysis, Inc. Key Market Participants
Call toll free 877 G O F ROST ( ) Fax toll free Visit For More Information